Critical Contrast: Actinium Pharmaceuticals (NYSE:ATNM) vs. NexImmune (OTCMKTS:NEXI)

NexImmune (OTCMKTS:NEXI) and Actinium Pharmaceuticals (NYSE:ATNM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for NexImmune and Actinium Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexImmune	0	0	0	0	0.00
Actinium Pharmaceuticals	0	0	1	0	3.00

Actinium Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 212.50%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than NexImmune.

Earnings and Valuation

This table compares NexImmune and Actinium Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexImmune	N/A	N/A	-$32.34 million	($18.29)	N/A
Actinium Pharmaceuticals	$90,000.00	443.68	-$48.82 million	($1.10)	-1.16

NexImmune has higher earnings, but lower revenue than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NexImmune has a beta of -2282.12, meaning that its share price is 228,312% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500.

Insider & Institutional Ownership

9.9% of NexImmune shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 14.9% of NexImmune shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares NexImmune and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NexImmune	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Actinium Pharmaceuticals beats NexImmune on 7 of the 11 factors compared between the two stocks.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.